智通财经APP获悉，中国同辐(01763)再涨超8%，年内股价累涨逾130%。截至发稿，涨7.94%，报24.48港元，成交额1302.97万港元。
消息面上，11月5日，诺华宣布其放射配体疗法（RLT）药物Pluvicto的两个适应症同时获得国家药监局批准。据悉，Pluvicto为诺华旗下的一款核药爆品。平安证券指出，Pluvicto的获批有望进一步点燃国内核医学行业热度，AD诊断核药有望随着治疗药物一同放量，建议关注国内在新核素和新靶点方面布局领先的企业，比如中国同辐等。
值得注意的是，10月31日，中国同辐发布碳同位素产品，标志我国在稳定同位素领域高端技术突破“卡脖子”难题，中国成为全球少数具备高丰度13CO气体和碳13尿素原料药生产能力的国家，公司成为完整掌握呼气试验产品全产业链的龙头企业。同日，公司正式启动稳定同位素基地二期项目建设。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.